8-K: Surgery Partners Reports Strong Q1 2024 Results and Raises Full-Year Guidance

Surgery Partners announced a 7.7% increase in revenue and an 8.2% increase in adjusted EBITDA for the first quarter of 2024, leading to an improved full-year outlook.

Summary

• Surgery Partners reported a 7.7% increase in revenue to $717.4 million for the first quarter of 2024, compared to $666.2 million in the same period last year.
• Same-facility revenues saw a significant 10.2% increase, driven by an 8.8% rise in revenue per case and a 1.3% increase in same-facility cases.
• The company's adjusted EBITDA reached $97.5 million, an 8.2% increase from $90.1 million in the first quarter of 2023.
• Adjusted EBITDA margin improved to 13.6% year-over-year.
• However, the company reported a net loss attributable to Surgery Partners, Inc. of $12.4 million.
• Surgery Partners has raised its full-year 2024 guidance, now projecting at least $3.05 billion in revenue and at least $505 million in adjusted EBITDA.
• The company completed several capital market transactions to strengthen its balance sheet and has no material debt maturities until 2030.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue and EBITDA growth, raised guidance, and successful debt refinancing. However, the net loss and decrease in operating cash flow temper the overall optimism.

Positives

• The company experienced strong revenue growth, with a 7.7% increase in total revenue and a 10.2% increase in same-facility revenue.
• Adjusted EBITDA saw an 8.2% increase, indicating improved profitability.
• The company successfully refinanced its debt, pushing out material maturities until 2030 and capping interest rate exposure.
• Surgery Partners raised its full-year guidance for both revenue and adjusted EBITDA, reflecting confidence in future performance.
• The company closed on several targeted acquisitions in late April, including a large system acquisition.

Negatives

• Surgery Partners reported a net loss attributable to the company of $12.4 million for the quarter.
• Cash flows from operating activities decreased to $40.7 million from $74.5 million in the prior year quarter, due to the timing of receivable collections.

Risks

• The company faces risks related to reductions in payments from government health care programs and private insurance payors.
• There are risks associated with maintaining relationships with physicians and integrating acquired businesses.
• Supply chain issues, competition, and the ability to attract and retain qualified healthcare professionals are ongoing concerns.
• The company is subject to legal and regulatory proceedings, as well as cybersecurity risks.
• The company's indebtedness and the impact of pandemics or epidemics pose potential challenges.

Future Outlook

The company has raised its full-year 2024 guidance to at least $3.05 billion in revenue and at least $505 million in adjusted EBITDA, indicating a positive outlook for the remainder of the year.

Management Comments

• Wayne DeVeydt, Executive Chairman, stated that the company is proud to report strong growth in Adjusted EBITDA and revenue, both ahead of expectations.
• Eric Evans, Chief Executive Officer, expressed confidence in continued future growth due to acquisitions, a robust de novo pipeline, and execution on key growth levers.
• Dave Doherty, Chief Financial Officer, highlighted the completion of multiple capital market transactions to enhance the balance sheet and manage interest rate exposure.

Industry Context

The announcement reflects a positive trend in the outpatient surgical services industry, with Surgery Partners demonstrating strong growth in a competitive market. The company's focus on acquisitions and operational efficiency aligns with industry trends towards consolidation and cost-effective healthcare delivery.

Comparison to Industry Standards

• Surgery Partners' same-facility revenue growth of 10.2% is strong compared to industry averages, which typically range from 3-7% for established healthcare providers.
• Companies like Tenet Healthcare and HCA Healthcare, which also operate surgical facilities, have reported similar growth in some segments but Surgery Partners' focused approach on short-stay surgical facilities appears to be yielding higher same-facility growth.
• The adjusted EBITDA margin of 13.6% is competitive, with industry leaders often reporting margins between 12-16%.
• The company's debt refinancing and interest rate hedging are proactive measures, aligning with best practices in financial management within the healthcare sector.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue and adjusted EBITDA guidance.
• Employees may benefit from the company's growth and expansion.
• Customers (patients) should experience continued access to high-quality surgical care.
• Physicians may find the company an attractive partner due to its growth and strategic focus.
• Creditors will likely view the debt refinancing and improved financial outlook favorably.

Next Steps

• The company will continue to focus on operational execution, physician recruiting, and strategic acquisitions.
• Surgery Partners will hold a conference call on May 7, 2024, to discuss the results.

Key Dates

Keywords

Surgery Partners, Surgical Facilities, Adjusted EBITDA, Revenue Growth, Healthcare Services, Acquisitions, Financial Results, Outpatient Surgery, Same-Facility Revenue, Debt Refinancing